文献速递心外重症与机械循环支持

左心室辅助装置桥接心脏移植前毛细血管前肺高压的可逆性与结局:UNOS 数据启示

Reversibility of precapillary pulmonary hypertension and outcomes after heart transplantation bridged with left ventricular assist devices: Insight from the United Network for Organ Sharing.
PubMed 文献 · J Thorac Cardiovasc Surg · 2024-03-05

基于 UNOS 数据库 2169 例 LVAD 桥接心脏移植受者,其中基线 PVR>2 者 1299 例,LVAD 植入后 551 例(42.4%)PVR 恢复正常≤2,748 例(57.6%)仍持续升高>2。女性及 listed 时使用正性肌力药与 PVR 持续升高相关,更长 LVAD 支持时间及 HeartMate II 使用为保护因素。LVAD 后 PVR 持续>2 者较恢复正常者死亡风险增高(aHR 1.26,95%CI 1.01-1.57,P=.037)。

要点

  • LVAD 桥接心脏移植受者中 57.6% 在 LVAD 后 PVR 仍持续>2 Wood 单位。
  • 女性及 listed 时使用正性肌力药与 PVR 持续升高相关。
  • LVAD 后 PVR 持续>2 者较恢复正常者死亡风险增高。

核心结论

  • 许多 LVAD 桥接心脏移植受者在 LVAD 植入后 PVR 仍>2,与 PVR 恢复正常者相比,心脏移植后死亡风险增高。

研究设计与样本

  • 基于 UNOS 数据库的回顾性研究,纳入 2169 例 LVAD 桥接心脏移植受者,其中基线 PVR>2 者 1299 例。

主要发现

  • 基线 PVR>2 的 1299 例中,551 例(42.4%)LVAD 后 PVR 恢复≤2,748 例(57.6%)PVR 仍>2。
  • 女性(aOR 2.22,95%CI 1.61-3.07,P<.001)及 listed 时使用正性肌力药(aOR 1.31,95%CI 1.03-1.66,P=.028)与 LVAD 后 PVR 持续升高相关。
  • 更长 LVAD 支持时间(aOR 0.74,95%CI 0.65-0.84,P<.001)及 HeartMate II 使用(aOR 0.74,95%CI 0.59-0.93,P=.011)为 LVAD 后 PVR 持续升高的保护因素。
  • LVAD 后 PVR 持续>2 者较 PVR 恢复正常者死亡风险增高(aHR 1.26,95%CI 1.01-1.57,P=.037)。
  • LVAD 后 PVR 恢复正常组与基线 PVR≤2 组生存相当(aHR 0.76,95%CI 0.57-1.02,P=.07)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In light of the updated lowered threshold for diagnosing pulmonary hypertension (PH), the reversibility of precapillary PH with left ventricular assist device (LVAD) and the associated post-heart transplantation (HT) outcomes remain unclear. METHODS: Using data from the United Network for Organ Sharing database, we aimed to investigate predictors of persistent precapillary PH in HT recipients bridged with LVAD and examine the interrelated post-HT survival using the updated pulmonary vascular resistance (PVR) cutoff of >2 Wood units for precapillary PH. RESULTS: Among 2169 HT recipients bridged with LVAD, 1299 had PVR >2 at baseline; 551 (42.4%) of whom normalized their PVR ≤2 and 748 (57.6%) remained with elevated PVR >2 after LVAD implantation. Female sex (adjusted odds ratio [aOR]; 2.22, 95% confidence interval [CI], 1.61-3.07; P < .001) and inotrope treatment at listing (aOR, 1.31; 95% CI, 1.03-1.66; P = .028) were associated with persistently elevated PVR after LVAD. Conversely, longer duration of LVAD support (aOR, 0.74; 95% CI, 0.65-0.84; P < .001) and use of HeartMate II (aOR, 0.74; CI, 0.59-0.93; P = .011) were found to be protective against persistently elevated PVR after LVAD. Persistently elevated PVR >2 after LVAD was associated with increased risk of death compared with those who normalized their PVR (adjusted hazard ratio [aHR], 1.26; 95% CI, 1.01-1.57; P = .037). However, the normalized PVR post-LVAD group had comparable survival with those with PVR ≤2 at baseline (aHR, 0.76; 95% CI, 0.57-1.02; P = .07). CONCLUSIONS: Many recipients of HT bridged with LVAD remain with PVR >2 after LVAD implantation, which is associated with increased risk of death after HT compared with patients with normalized PVR after LVAD.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Alnsasra H, Perue RK, Khalil F, et al. Reversibility of precapillary pulmonary hypertension and outcomes after heart transplantation bridged with left ventricular assist devices: Insight from the United Network for Organ Sharing. J Thorac Cardiovasc Surg. 2024. PMID: 38452886. doi:10.1016/j.jtcvs.2024.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。